Varian gains more worldwide sites for RapidArc system

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

Varian gains more worldwide sites for RapidArc system

Varian Medical Systems has placed its RapidArc Radiotherapy unit at the following institutions:
• Bern University Hospital in Bern, Switzerland
• Chang Gung Memorial Hospital in Linkou, Taiwan
• Gottingen University Hospital in Gottingen, Germany
• Innovative Cancer Institute in S. Miami, Fla.
• Lehigh Valley Health Network in Allentown and Bethlehem, Penn.
• New Mexico Cancer Center in Albuquerque
• Northwoods Cancer Center in Woodlands, Tex.
• Pamela Youde Nethersole Eastern Hospital in Hong Kong
• Sudharz Krankenhaus in Nordhausen, Germany
• Trinitas Comprehensive Cancer Center in Elizabeth, N.J.
• Zurich University Hospital

Articles in this issue
Drug with tumor-specific target fells cancerous B cells while sparing healthy ones in NHL
Expanded Medicare coverage of PET draws kudos from oncology community
Who's News
Push for comparative effectiveness research
Should lymphadenectomy be the standard of care in melanoma metastasis to the sentinel lymph nodes?
Lack of persuasive data continues to plague PSA testing
Aggressive colon cancer treatment: A matter of tolerability vs necessity
Less toxic protocol proves efficacious in chronic lymphocytic leukemia pts
ASCO draws road map to navigate economic, racial disparities in ca care
Clinical trials flourish in international setting
Global lung ca staging lexicon undergoes major overhaul
Decision-analytic model aids cervical cancer treatment
Elekta pledges $1 million to support RT research
Varian gains more worldwide sites for RapidArc system
Focus on Lung Cancer
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Related Content
FDA Approves PET Imaging Agent for Prostate Cancer

FDA Approves PET Imaging Agent for Prostate Cancer

Ariana Pelosci
March 21st 2025
Article

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Ariana Pelosci
March 20th 2025
Article

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

FDA Grants Fast Track Designation to Azer-cel in R/R DLBCL

FDA Grants Fast Track Designation to Azer-cel in R/R DLBCL

Tim Cortese
March 20th 2025
Article

Azer-cel elicited strong and durable responses in patients with heavily pretreated relapsed/refractory DLBCL in a phase 1b trial.

Evaluation of the 1-year overall survival data in the phase 3 ARES trial assessing MaaT013 in GVHD is expected to occur Q4 2025.

EMA DSMB Confirms MaaT013 Efficacy/Benefit in GI-aGvHD

Roman Fabbricatore
March 20th 2025
Article

Evaluation of the 1-year overall survival data in the phase 3 ARES trial assessing MaaT013 in GVHD is expected to occur Q4 2025.